Lyell Immunopharma, Inc. Common Stock
$11.01
Market Cap
$269.80M
Shares Outstanding
24.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 17, 2021
Round Lot
100
Locale
US
Day Open
$10.75
Day High
$11.04
Day Low
$10.53
Volume
401.1K
VWAP
$10.91
Prev Close
$10.80
Transactions
--
Acc. Volume
--
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Lyell Immunopharma, Inc. Common Stock (LYEL) closed the 2026-09-18 session at $11.01, up 1.94% versus the previous close (+0.21). The stock opened at $10.75 and traded between $10.53 and $11.04 during that session. Session trading volume was 401K shares. The volume-weighted average price (VWAP) is $10.91.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Lyell Immunopharma, Inc. Common Stock has a market capitalization of $269.8 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. LYEL is listed on the XNAS exchange. The company employs approximately 161 people. Lyell Immunopharma, Inc. Common Stock is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2021-06-17.
On this page you can find market LYEL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.